Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome
ODYSSEY OUTCOMES Trial
J. Wouter Jukema, Michael Szarek, Laurien E. Zijlstra, H. Asita de Silva, Deepak L. Bhatt, Vera A. Bittner, Rafael Diaz, Jay M. Edelberg, Shaun G. Goodman, Corinne Hanotin, Robert A. Harrington, Yuri Karpov, Angèle Moryusef, Robert Pordy, Juan C. Prieto, Matthew T. Roe, Harvey D. White, Andreas M. Zeiher, Gregory G. Schwartz, P. Gabriel Steg and for the ODYSSEY OUTCOMES Committees and Investigators‡
Alirocumab and Vascular Disease: Primary Major Adverse Cardiovascular Event Endpoint
Kaplan-Meier curves for primary major adverse cardiovascular event (MACE) endpoint in patients with arterial disease in, respectively, 1 (coronary artery disease (CAD) and no peripheral artery disease (PAD) or cerebrovascular disease (CeVD)), 2 (CAD and PAD or CeVD), or 3 (CAD and PAD and CeVD) vascular beds. CI = confidence interval.